Navigation Links
SCOLR Pharma, Inc. Reports Second Quarter 2009 Financial Results
Date:8/7/2009

y income increased 34%, or $59,017 to $230,789 in the three months ended June 30, 2009, compared to $171,772 for the first quarter of 2009. This increase is a result of higher sales activities of our nutritional products by Perrigo. Royalty payments are based on Perrigo's net profits from the sale of CDT-based products which involve uncertainties and are difficult to predict.

Total revenues decreased 26%, or $142,565 to $402,561 for the six months ended June 30, 2009, compared to $545,126 for the same period in 2008. This decrease is primarily due to lower royalty income from our relationship with Perrigo.

Marketing and selling expenses decreased 79%, or $151,579 to $39,468 for the three months ended June 30, 2009, compared to $191,047 for the same period in 2008 and decreased 66%, or $282,688 to $146,051 for the six months ended June 30, 2009, compared to $428,739 for the same period in 2008. These decreases are due to a reduction in personnel related expenses due to reduction in personnel and lower advertising and tradeshow expenses. In addition, commission expense decreased due to lower royalty income.

Research and development expenses decreased 34%, or $403,818 to $793,503 for the three months ended June 30, 2009, compared to $1.2 million for the same period in 2008 and decreased 22%, or $465,096 to $1.6 million for the six months ended June 30, 2009, compared to $2.1 million for the same period in 2008. These decreases were primarily due to our decision to defer development activities on certain projects pending additional funding and a reduction in personnel related expenses due to personnel reductions. These decreases were offset by an expense related to settlement of claims by a former employee.

General and administrative expenses decreased 8%, or $89,762 to $972,884 for the three months ended June 30, 2009, compared to $1.1 million for the same period in 2008 and decreased 7%, o
'/>"/>

SOURCE SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. SCOLR Pharma, Inc. Reports Fourth Quarter 2008 Financial Results
2. FDA Issues Complete Response Letter to SCOLR Pharmas Abbreviated New Drug Application for CDT(R) 12-Hour Pseudoephedrine
3. SCOLR Pharma, Inc. to Present at the Rodman & Renshaw 10th Annual Healthcare Conference
4. SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results
5. SCOLR Pharma, Inc. Schedules Second Quarter 2008 Financial Results Conference Call for August 7, 2008 at 11:30 A.M. Eastern
6. ULURU Discussions to Acquire York Pharma, plc Are Currently Terminated
7. CutisPharma, Inc. Receives Verified Accreditation for Wholesale Distributors from the National Association of Boards of Pharmacy for Woburn Facility
8. Strativas Development Partner, BioAlliance Pharma, Submits Loramyc(R) NDA
9. Evoke Pharma, Inc. Initiates Phase 2b Metoclopramide Intranasal Trial (MINT) in Patients With Diabetic Gastroparesis
10. Sinobiopharma, Inc. Appoints New Director of Marketing
11. Houlihan Smith Arranges Non-Control Equity Investment Into Sottera, Inc., dba NJOY, by Miri Pharma, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... NEW YORK , July 29, 2015 /PRNewswire/ ... neuropathology testing, announces increased partnerships with VA and ... offers Epidermal Nerve Fiber Density (ENFD) and Sweat ... of small fiber neuropathy ( https://therapath.com/skin ). ... Epidermal Nerve Fiber Density (ENFD) on punch skin ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: INDV) ... naloxone nasal spray was accepted and received Priority Review ... the treatment of opioid overdose. This naloxone nasal spray ... formulated for optimal absorption into the nasal mucosa. 1 ... training so individuals may be better equipped to help ...
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... company, is pleased to announce that the final design ... been locked.  Prototypes for industrial and regulatory testing ... application for CE mark clearance to market the ... 2016. (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  ...
(Date:7/29/2015)... ... 29, 2015 , ... Finding gooey or crusty material in the corner of ... a considerable number of terms in popular use to describe it, ophthalmologists call it ... of mucus, blood cells, skin cells and dust, but until now there has been ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4
... 7 BD (Becton,Dickinson and Company) (NYSE: BDX ), a ... following investor healthcare,conferences:, Bank of America 2008 ... 11:40 a.m. EDT, Bernstein 24th Annual Strategic Decisions ... 8:00 a.m. EDT A live webcast of BD,s presentations can ...
... Arena Pharmaceuticals, Inc.,(Nasdaq: ARNA ) today reported ... Total revenues in the first quarter of 2008 ... quarter of 2007, and included $2.0 million in,revenue under ... in patent reimbursements from Arena,s collaborations with,Merck & Co., ...
... Building a comprehensive and,coherent corporate brand and ... a critical step to developing a pipeline of,potential ... talent during this time of increased cost consciousness ... today., You are invited to discuss these ...
Cached Biology Technology:Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 2Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 3Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 4Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 5Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 6Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 7Arena Pharmaceuticals Announces First Quarter 2008 Financial Results 8Group Hotel Rate Ends Friday: Reserve Now for Leadership Development Conference June 4-6 2
(Date:7/2/2015)... -- Research and Markets( http://www.researchandmarkets.com/research/km7m5t/natural_language ... "Natural Language Processing Market by Type (Rule-Based, Statistical, ... Image Recognition) - Worldwide Forecast to 2020" ... vendors occupying the market are 3M, Apple, Dolbey ... Solutions, SAS Institute Inc., Verint Systems among various ...
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
(Date:6/26/2015)... ATL Technology, LLC, a top provider of electromechanical contract manufacturing ... headquartered in Springville, Utah , has announced ... corporation with locations in Santa Clara, CA ... ). This acquisition will incorporate MedConx,s manufacturing facility ... existing facility in Costa Rica , resulting ...
Breaking Biology News(10 mins):Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2
... of thousands of albatrosses and other far-ranging seabirds are killed ... Innovative new models developed by a Duke University-led research team ... where and when birds and boats are likely to cross ... data to predict changing conditions such as sea surface ...
... of ancient enzymes adapted to substantial changes in ocean ... providing evidence that life on Early Earth evolved from ... less acidic global environment that exists today. The ... as thioredoxin were chemically stable at temperatures up to ...
... Researchers at the University of Massachusetts Medical School ... protein IFT88 in mitosis, the process by which a ... into two identical sets of new daughter cells. Published ... this newly discovered function for IFT88 suggests a possible ...
Cached Biology News:New models may reduce seabird bycatch 2Protein adaptation shows that life on early earth lived in a hot, acidic environment 2Protein adaptation shows that life on early earth lived in a hot, acidic environment 3Protein adaptation shows that life on early earth lived in a hot, acidic environment 4Researchers identify new role for cilia protein in mitosis 2
... uses three Adept CE 4100 high pressure ... rate in one microlitre increaments. The ... provides added flexibility. The WaveQuest ... array detection and provides superior stability . ...
... of samples may be carried out using this ... System control and data processing is provided ... The elegant, powerful and very easy to use ... and 2000., The supplied detector is the ground ...
...
capacity 250 mL...
Biology Products: